InhaleRx Executes Study Order for Panic Disorder Drug Candidate; Shares Hit All-Time Low

MT Newswires Live

Apr 17

InhaleRx (ASX:IRX) formally executed a study order with iNGENu CRO as the contract research organization to oversee its phase one clinical trial of IRX-616a, a drug candidate for panic disorder, according to a Thursday Australian bourse filing.

The study is a randomized, double-blind, placebo-controlled, single ascending dose trial seeking to evaluate the pharmacokinetics, safety, and tolerability of the IRX-616a cannabidiol inhaler in healthy volunteers, the filing said.

The firm plans to procure the manufacturing of the drug candidate and finalize all documentation for a human research ethics committee approval, per the filing.

InhaleRx's shares jumped over 22% in recent trading on Thursday, earlier hitting an all-time low.

Price (AUD): $0.02, Change: $+0.0040, Percent Change: +22.22%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2528275582"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2528275582\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2528275582?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-17 13:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2528275582","market":"hk","top_or_hot":-1,"title":"InhaleRx Executes Study Order for Panic Disorder Drug Candidate; Shares Hit All-Time Low","media":"MT Newswires Live","content":"<html><body><p> InhaleRx (ASX:IRX) formally executed a study order with iNGENu CRO as the contract research organization to oversee its phase one clinical trial of IRX-616a, a drug candidate for panic disorder, according to a Thursday Australian bourse filing.</p><p>The study is a randomized, double-blind, placebo-controlled, single ascending dose trial seeking to evaluate the pharmacokinetics, safety, and tolerability of the IRX-616a cannabidiol inhaler in healthy volunteers, the filing said.</p><p>The firm plans to procure the manufacturing of the drug candidate and finalize all documentation for a human research ethics committee approval, per the filing.</p><p>InhaleRx's shares jumped over 22% in recent trading on Thursday, earlier hitting an all-time low.</p><p>Price (AUD): $0.02, Change: $+0.0040, Percent Change: +22.22%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>InhaleRx Executes Study Order for Panic Disorder Drug Candidate; Shares Hit All-Time Low</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInhaleRx Executes Study Order for Panic Disorder Drug Candidate; Shares Hit All-Time Low\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-04-17 13:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> InhaleRx (ASX:IRX) formally executed a study order with iNGENu CRO as the contract research organization to oversee its phase one clinical trial of IRX-616a, a drug candidate for panic disorder, according to a Thursday Australian bourse filing.</p><p>The study is a randomized, double-blind, placebo-controlled, single ascending dose trial seeking to evaluate the pharmacokinetics, safety, and tolerability of the IRX-616a cannabidiol inhaler in healthy volunteers, the filing said.</p><p>The firm plans to procure the manufacturing of the drug candidate and finalize all documentation for a human research ethics committee approval, per the filing.</p><p>InhaleRx's shares jumped over 22% in recent trading on Thursday, earlier hitting an all-time low.</p><p>Price (AUD): $0.02, Change: $+0.0040, Percent Change: +22.22%</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IRX.AU","symbol_name":"INHALERX LIMITED","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2528275582","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2528275582","pubTimestamp":1744868863,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"InhaleRx  formally executed a study order with iNGENu CRO as the contract research organization to oversee its phase one clinical trial of IRX-616a, a drug candidate for panic disorder, according to a Thursday Australian bourse filing.The study is a randomized, double-blind, placebo-controlled, single ascending dose trial seeking to evaluate the pharmacokinetics, safety, and tolerability of the IRX-616a cannabidiol inhaler in healthy volunteers, the filing said.The firm plans to procure the manufacturing of the drug candidate and finalize all documentation for a human research ethics committee approval, per the filing.InhaleRx's shares jumped over 22% in recent trading on Thursday, earlier hitting an all-time low.Price : $0.02, Change: $+0.0040, Percent Change: +22.22%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IRX.AU":"INHALERX LIMITED","BK7007":"医疗保健设备","BK7094":"医疗保健技术"},"translate_title":"InhaleRx执行恐慌症候选药物的研究订单；股价创历史新低","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IRX.AU":0.9},"content_text":"InhaleRx (ASX:IRX) formally executed a study order with iNGENu CRO as the contract research organization to oversee its phase one clinical trial of IRX-616a, a drug candidate for panic disorder, according to a Thursday Australian bourse filing.The study is a randomized, double-blind, placebo-controlled, single ascending dose trial seeking to evaluate the pharmacokinetics, safety, and tolerability of the IRX-616a cannabidiol inhaler in healthy volunteers, the filing said.The firm plans to procure the manufacturing of the drug candidate and finalize all documentation for a human research ethics committee approval, per the filing.InhaleRx's shares jumped over 22% in recent trading on Thursday, earlier hitting an all-time low.Price (AUD): $0.02, Change: $+0.0040, Percent Change: +22.22%","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}